Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Cassava Sciences is a clinical-stage biotechnology company focused on developing simufilam, an investigational oral drug targeting Alzheimer's disease by restoring altered filamin A protein. The company has no commercial revenue and operates as a pure R&D entity dependent on clinical trial outcomes, regulatory approvals, and capital markets access. Following significant scientific controversy, FDA investigations, and failed Phase 3 trials announced in 2024-2025, the company faces existential uncertainty with depleted market capitalization and limited runway.
Cassava operates a binary-outcome business model typical of clinical-stage biotech: invest capital in R&D to advance drug candidates through FDA trials (Phase 1/2/3), seek regulatory approval, then commercialize or partner for distribution. The company's entire value proposition rests on simufilam's mechanism of action (restoring filamin A to reduce neuroinflammation and neurodegeneration) proving clinically effective and commercially viable. With no diversified pipeline, success requires positive Phase 3 data, FDA approval, and market penetration in the highly competitive Alzheimer's space dominated by Biogen, Eli Lilly, and Eisai. Monetization would occur through direct sales, royalty agreements, or acquisition by larger pharma.
Clinical trial data releases and interim analysis results for simufilam Phase 3 studies
FDA communications including clinical hold decisions, Complete Response Letters, or approval pathway guidance
Scientific publications addressing mechanism of action validity and data integrity concerns raised by critics
Capital raises, partnership announcements, or liquidity events given limited cash runway
Litigation outcomes related to securities fraud allegations and scientific misconduct investigations
Competitive developments in Alzheimer's treatment landscape (Leqembi, Kisunla approvals impact positioning)
Single-asset dependency: Entire enterprise value tied to simufilam with no pipeline diversification, creating binary outcome risk where trial failure equals potential bankruptcy
Scientific credibility crisis: Ongoing allegations of data manipulation, journal article concerns, and citizen petitions to FDA create reputational overhang affecting partnership prospects and investor confidence
Regulatory pathway uncertainty: FDA scrutiny following integrity concerns may impose higher evidentiary standards or additional trial requirements, extending timelines and capital needs beyond company resources
Alzheimer's treatment paradigm shift: Amyloid-targeting therapies (Leqembi, Aduhelm) have shown modest efficacy with significant side effects, potentially limiting commercial opportunity even if simufilam achieves approval
Established competitors with approved therapies: Biogen/Eisai (Leqembi), Eli Lilly (Kisunla) have first-mover advantage, established reimbursement pathways, and infrastructure Cassava lacks
Well-funded pipeline competition: Dozens of Alzheimer's programs from major pharma with superior balance sheets, diversified portfolios, and commercialization capabilities
Mechanism of action skepticism: Filamin A hypothesis lacks broad scientific validation compared to amyloid/tau pathways, creating adoption barriers even if approved
Liquidity crisis risk: $100M market cap with $100M annual cash burn implies less than 12 months runway at current burn rate, requiring imminent capital raise
Dilution spiral: Depressed stock price (-78% from highs) forces highly dilutive equity raises, creating death spiral risk where each financing further impairs existing shareholders
Going concern uncertainty: Auditors may issue going concern qualification if adequate financing not secured, triggering delisting risk and further capital markets closure
low - Clinical-stage biotech operates independently of GDP cycles as R&D timelines are driven by regulatory processes, not economic demand. However, capital markets access for funding is cyclically sensitive: risk-off environments reduce investor appetite for speculative biotech, tightening financing conditions and potentially forcing unfavorable dilution or operational cuts.
Rising interest rates negatively impact Cassava through two channels: (1) Higher discount rates compress NPV of distant future cash flows, disproportionately affecting pre-revenue biotech valued on long-dated commercialization scenarios; (2) Risk-free rate competition makes speculative equities less attractive, reducing capital availability and increasing cost of equity financing. With 2.27x current ratio and negative $100M operating cash flow, the company requires external capital, making rate environment critical.
Minimal direct credit exposure given zero debt (0.00 Debt/Equity ratio). However, equity capital markets conditions are critical: tighter credit spreads and risk appetite in biotech financing markets determine ability to raise survival capital. High-yield spreads serve as proxy for risk sentiment affecting speculative equity issuance.
speculation - Cassava attracts high-risk tolerance investors seeking asymmetric payoff from binary clinical outcomes, retail momentum traders responding to trial catalysts, and short sellers betting on scientific invalidity. The collapsed valuation and controversy have eliminated institutional quality growth investors. Current holder base likely comprises bagholders from $100+ prices, contrarian value speculators betting on vindication, and active short interest. Not suitable for fundamental value or income investors given no cash flows, profitability, or dividends.
high - Clinical-stage biotech with single-asset risk, ongoing litigation, and scientific controversy exhibits extreme volatility. Stock has demonstrated 50%+ intraday swings on trial updates. Implied volatility likely exceeds 100% annualized. Beta to broader market is low (company-specific risk dominates), but absolute volatility is extreme.
